11th International Congress on Drug Therapy in HIV Infection (HIV11)

11th International Congress on Drug Therapy in HIV Infection (HIV11)

November 11-15, 2012, Glasgow

HIV11: UK Study Finds HIV+ Women on Antiretroviral Therapy Have Higher Premature Birth Rate

A review of clinical records from Central Manchester University Hospitals has found more evidence of an increased rate of preterm delivery of babies born to HIV positive women who are taking antiretroviral therapy (ART), according to a study presented at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow this month. alt

Read more:

HIV11: Life Expectancy in Older People with HIV Could Exceed the Average - As Long As ART Keeps Working

The latest forecasts of life expectancy in people with HIV in the U.K., based on mortality data from the UK Collaborative HIV Cohort (UK CHIC) study, show that the average life expectancy of people on antiretroviral therapy (ART) with a CD4 count over 350 cells/mm3 is now very close to the national average, the 11th International Congress on Drug Therapy in HIV Infection in Glasgow heard last week. alt

Read more:

Coverage of 11th International Congress on Drug Therapy in HIV Infection

HIVandHepatitis.com coverage of the 11th International Congress on Drug Therapy in HIV Infection (HIV11), November 11-15, 2012, Glasgow, Scotland.

Conference highlights include experimental antiretroviral drugs, ART strategies, manging side effects, HIV-related non-AIDS conditions, treatment as prevention and PrEP, HIV/HCV coinfection, and the search for a cure for HIV.

Full listing by topic

HIVandHepatitis.com HIV11 conference section

11/17/12

alt

HIV11: Complera Combo Pill as Effective as Atripla for First HIV Treatment, but Better Tolerability

The Complera (rilpivirine/tenofovir/emtricitabine) single-tablet regimen suppressed HIV as well as the Atripla (efavirenz/tenofovir/emtricitabine) combination pill in treatment-naive people, but led to fewer adverse events -- in particular neuropsychiatric side effects associated with efavirenz, according to a report at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) last week in Glasgow. alt

Read more:

HIV11: Infants Who Start Antiretrovirals Early Keep HIV Suppressed Despite Treatment Interruption

Babies who started taking lopinavir-based antiretroviral therapy (ART) soon after they were diagnosed with HIV experienced good virological response that was sustained through 6 years, even after they stopped treatment, according to long-term data from the CHER study presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.alt

Read more: